Literature DB >> 2024957

Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine.

F Derouin1, C Piketty, C Chastang, F Chau, B Rouveix, J J Pocidalo.   

Abstract

The efficacy of dapsone alone or combined with pyrimethamine against Toxoplasma gondii was investigated experimentally. For in vitro studies, a sensitive immunoassay was used for assessment of Toxoplasma growth in tissue cultures; dapsone was found to have a significant inhibitory effect at a concentration of 0.5 micrograms/ml in the cultures, and the 50% inhibitory concentration was estimated to be 0.55 micrograms/ml. When pyrimethamine and dapsone were combined, an important synergistic effect which was associated with morphological alterations of the parasites was observed. In vivo studies were performed in a murine model of acute toxoplasmosis in which a tissue culture method was used to estimate the parasite burden in the blood, lungs, and brains of infected mice. Dapsone alone, which was administered at 100 mg/kg/day for 10 days from day 1 after infection, was unable to prevent parasite dissemination and only delayed the time to death of treated mice compared with the time of death of untreated controls. When dapsone and pyrimethamine (18.5 mg/kg/day) were administered in combination from day 4 after infection, parasites were cleared from blood and organs within 6 days, but relapses were observed 15 days after the cessation of therapy. When treatment was started at day 1 after infection, 100% of mice survived and relapses were not observed, suggesting a good efficacy of this combination for preventive therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024957      PMCID: PMC244986          DOI: 10.1128/AAC.35.2.252

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus.

Authors:  C R Lucas; A M Sandland; A Mijch; J M Simpson
Journal:  Med J Aust       Date:  1989-07-03       Impact factor: 7.738

2.  The effects of oral administration of aureomycin, sulfathiazole, sulfamerazine and 4,4'-diamino diphenyl sulfone on toxoplasmosis in mice.

Authors:  W A SUMMERS
Journal:  Am J Trop Med Hyg       Date:  1949-11       Impact factor: 2.345

3.  Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.

Authors:  B L Lee; I Medina; N L Benowitz; P Jacob; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1989-04-15       Impact factor: 25.391

4.  The pharmacokinetics of dapsone after oral administration to healthy volunteers.

Authors:  F A Pieters; J Zuidema
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  J Mills; G Leoung; I Medina; P C Hopewell; W T Hughes; C Wofsy
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.

Authors:  S K Garg; B Kumar; V Bakaya; R Lal; V K Shukla; S Kaur
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1988-11

8.  Prophylactic effect of 2-sulfamoyl-4,4'-diaminodiphenylsulfone (SDDS) on experimental infection with Toxoplasma in pigs.

Authors:  S Oshima; Y Inami; H Tanaka
Journal:  Am J Trop Med Hyg       Date:  1970-05       Impact factor: 2.345

9.  Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J M Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  9 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

2.  Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour.

Authors:  J P Webster; P H L Lamberton; C A Donnelly; E F Torrey
Journal:  Proc Biol Sci       Date:  2006-04-22       Impact factor: 5.349

3.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.

Authors:  M Brun-Pascaud; F Chau; L Garry; D Jacobus; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 5.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

Authors:  M Opravil; B Joos; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 8.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

9.  In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis.

Authors:  Seon-Ju Yeo; ChunMei Jin; SungYeon Kim; Hyun Park
Journal:  Korean J Parasitol       Date:  2016-04-30       Impact factor: 1.341

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.